Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
no vol. today
Now at $ 24,35 vol 100
The world is changed, I feel it in the water, I feel it in the earth. I smell it in the air.
And I hope to see it on my accont
Good news!
David Carbone at ESMO Immuno-Oncology, 21-22 Nov.2014, Geneve
22. Nov. at 11:30
http://www.esmo.org/content/download/41727/790129/file/ESMO-Symposium-on-Immuno-Oncology-2014-Programme.pdf
Chugai soars on report of talks to become Roche's 100 pct unit 4519.T ROG.VX - RTRS
18-Aug-2014 03:14
TOKYO, Aug 18 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T shares rose 21 percent to a record high following a media report that Roche Holding AG ROG.VX is in talks to buy the almost 40 percent stake in the Japanese firm that it doesn't already own for about $10 billion.
Shares of Chugai were up 20 percent at 3,985 yen as of 0106 GMT after touching 4,015 yen, exceeding the previous record of 3,510 yen set last month.
The Swiss group could announce a deal to take full control of its Japanese partner for oncology and arthritis drugs as early as this week, although no final decision has been made, Bloomberg reported.
In a statement, Chugai denied it was holding such discussions with Roche, while a spokeswoman for Roche declined to comment on the report. (Full Story)
Roche - Avastin
Drug Is Approved as Treatment for Cervical Cancer - NYTIME
18-Aug-2014 18:21
The Food and Drug Administration has approved Avastin — made by Genentech , a unit of the Swiss drug maker Roche — for a new use against late-stage cervical cancer, the seventh indication for the biotech drug, which had global sales of $6.25 billion last year. Avastin works by choking off blood vessels that help new cancer cells grow. The F.D.A. approved the drug on Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body. The new use is approved in combination with the chemotherapy drugs paclitaxel and cisplatin or in combination with paclitaxel and topotecan. Avastin is already approved for various forms of colon cancer, lung cancer, glioblastoma and kidney cancer. The National Cancer Institute estimates that over 12,300 women in the United States will receive a diagnosis of cervical cancer this year and 4,000 will die from the disease.
realy? - i see exciting month coming!
But both of them are in Madrid - ESMO
Mayby there!!???
Nothing to read from Kyoto - maybe they are not there
http://www.investor.bayer.de/en/events/calendar/
http://www.bayerpharma.com/de/partnering/wo-sie-uns-treffen/index.php
200 MA is at 1,70 and 50 MA at 1,71 - hard nut
San Franciso and Kyoto coming in about two/three weeks - will we see increasing vol?
i know - but their MCap was much higher at that time! So what.....
ICPT - from Jan.2014
Intercept liver disease drug meets main goal in study, shares soar ICPT.O - RTRS
09-Jan-2014 14:07
Jan 9 (Reuters) - Intercept Pharmaceuticals Inc ICPT.O said an analysis by an independent safety committee showed that its liver disease drug met the main goal of a mid-stage trial, sending the company's shares soaring.
Intercept shares more than doubled to $169 in premarket trading on Thursday.
The company said it had stopped the trial after the committee found that the drug, obeticholic acid, showed statistically significant improvement in patients, compared with a placebo. (Full Story)
Nasdaq-listed Intercept said the committee made the recommendation after reviewing liver biopsy data from about half of the 283 patients enrolled in the trial.
The trial tested the drug in patients with non-alcoholic steatohepatitis, a form of liver inflammation caused by a build-up of fat.
It went from 70 to 300 and the next day from 300 to 500 - nice!
September is coming soon - i think i will place an stop-buy-order at $2,05
absolutely correct
PM $1,67 2k
OK!!! Thx, because CP wrote "monday"
So, than the Diamond Sponsor Symposium is on MONDAY the 8. Sept. 2014!?
CP, is the Bayer Symposium part of Kyoto???
Is this new for you - your english is better:
http://www.pnas.org/content/early/2014/08/07/1319488111
short interest 31.7.2014:
http://www.nasdaq.com/symbol/pphm/short-interest
we fight for love and glory - an for $ 1,70
1,76 $
And the pps goes to: 1,71
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression PPHM.O - MKW
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression PPHM.O - MKW
11-Aug-2014 14:00
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/pdfnews/pdfnews.asp...
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Combination Mediated Impressive Increase in Tumor-Fighting T-Cells and Significantly Reduce Tumor Growth by Over 78% as Compared to Anti-PD-1 Alone; Combination Data Show Synergies That Enhance the Effectiveness of Recently Approved and Experimental Immuno-Oncology Treatments That Extend the Duration and Effectiveness of Tumor Fighting T-Cells; Results Build on Data Seen in Studies Combining Bavituximab With Anti-CTLA-4 or Anti-PD-1 Antibody in Models of Melanoma and Colon Cancer
TUSTIN, CA--(Marketwired - Aug 11, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at
12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being
held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being
evaluated in second-line non-small cell lung cancer (NSCLC) as part of the
SUNRISE pivotal Phase III clinical trial.
"These statistically significant results are an important extension of earlier data obtained combining our PS-targeting antibodies with other immune checkpoint inhibitors in different tumor types and our clinical experience in treating breast cancer patients," said Jeff Hutchins, Ph.D., vice president of preclinical research at Peregrine and the study's presenter. "These data further validate that blocking the immunosuppressive effects of PS facilitate an increase in tumor-fighting T-cells, and that the combination with PD-1 then allows for a more effective anti-tumor T-cell response. We believe these studies, along with our previously released Phase II breast cancer results, warrant an expanded clinical investigation in breast cancer that would build on our ongoing immunotherapy combination clinical trial in advanced melanoma."
In a presentation titled: "Phosphatidylserine (PS)-Targeting Antibodies Enhance Activity of Immune Checkpoint Inhibitors by Repolarizing Immunosuppressive Immune Cells Populating the Tumor Microenvironment", Dr. Hutchins will provide an overview of the company's PS-targeting platform including preclinical data emerging from the company's immuno-oncology development program. This presentation includes new data showing that animals treated with the PS-targeting antibody ch1N11, the preclinical equivalent to bavituximab, in combination with anti-PD-1 in an EMT-6 mouse breast tumor model, significantly delayed the treatments group median tumor growth compared to anti-PD-1 alone. Specifically, following once weekly treatments of ch1N11 plus anti-PD-1, tumor growth was inhibited by 78.7% (p= 0.0048 on day 23) compared anti-PD-1 alone. In addition, 50% of the tumors treated with the combination either regressed or did not progress compared to 0% for anti-PD-1 alone. Also, the once weekly combination treatment with ch1N11 and anti-PD-1 led to a 78% and 81% increase in intratumoral CD4+ and CD8+ T cells, two key indicators that show that tumor fighting immune cells are present in the local tumor environment, compared to the single agent anti-PD-1.
"With these combination results, we are clearly seeing both a significant delay in tumor growth as a group and a decrease in the number of animals with tumor progression," said Bruce Freimark, Ph.D., director of pre-clinical research in oncology. "We believe these data present encouraging observations to support the expanded clinical use of tumor immunotherapy combinations using PS-targeting antibodies."
A copy of Dr. Hutchins' presentation is available on the company's website at www.peregrineinc.com.
About Bavituximab: A Targeted Investigational Immunotherapy
Scientific research has shown that tumors evade immune detection due partly to the expression of phosphatidylserine, or PS, a highly immunosuppressive molecule exploited by tumors. Peregrine's immuno-oncology development program has developed bavituximab, an investigational PS-targeting monoclonal antibody that targets and binds to PS and blocks the immunosuppressive effects of PS while activating tumor fighting immune cells, thus enabling the immune system ability to recognize and fight cancer. Bavituximab's immune-stimulatory mechanism-of-action data is the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) peer-reviewed journal, Cancer Immunology Research. Bavituximab is currently being evaluated in several solid tumor indications, including non-small cell lung cancer, breast cancer, liver cancer, rectal cancer and advanced melanoma. In January 2014, bavituximab received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of second-line non-small cell lung cancer.
About The SUNRISE Trial
SUNRISE is a pivotal Phase III, randomized, placebo-controlled, double-blind, multinational clinical trial evaluating the efficacy and safety of bavituximab, a novel investigational immunotherapy, plus docetaxel versus placebo plus docetaxel as a second-line treatment for patients with Stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC). For additional information about the SUNRISE trial please visit www.sunrisetrial.com or ClinicalTrials.gov using the Identifier NCT01999673.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from potential human clinical studies involving combinations of bavituximab with PD-1 antibodies may not correlate with the data from the preclinical studies. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies, including the Phase III SUNRISE trial; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the SEC including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
and one day later (8. Sep.) there is a pphm-CC - Q1 Earings Release
AND: Kyoto Liver conf.
http://www.ilca2014.org/
that was always a bad sign or NO SIGN
i think most of us own more
i hope it will be more then 90 m
the worldrecord ist over 200 m and i hope, that we will see that in the coming 9 months - pphm fly me/us to the moon!
We are at: 124 Loc.
http://www.clinicaltrials.gov/ct2/show/NCT01999673?term=bavituximab&rank=8
"lackluster and unreliable Phase II data"
not so nice!
but wait until next summer
thx and all the best for you, pphm and us!
we´l see it in the coming 6 - 9 months
We are at 123 loc.